New research released in 2025 strengthens concerns about marijuana’s impact on heart health. Large-scale studies show cannabis users face higher risks of heart attack, stroke, and cardiovascular death compared with non-users. These findings arrive as Thailand debates cannabis regulation and public health messaging amid growing access to medical cannabis and ongoing questions about recreational use.
Recent analyses indicate that marijuana’s active compounds, especially THC, can affect blood vessels, heart rate, and blood pressure. In Thailand, where medicinal cannabis was legalized in 2022 and recreational use remains unresolved, experts say the new evidence underscores the need for careful policy making and consumer education. Public health officials note that the tone of messaging around cannabis—often framed as “natural medicine”—must now include clear information about cardiovascular risks.
Key studies published in 2024 and 2025 point to meaningful increases in risk. A major review in Heart suggests cannabis users have about a 29% higher risk of heart attacks, roughly 20% higher risk of strokes, and a higher likelihood of cardiovascular death versus non-users. Other research cited by major outlets finds daily cannabis use associated with a substantially higher chance of heart attack and stroke. While researchers caution that risk levels vary, the pattern indicates that any level of use—occasional or regular—can influence cardiovascular health, particularly for those with pre-existing heart conditions or tobacco use.
For Thai readers, the message is both urgent and practical. Thailand’s public health community emphasizes that cannabis is not risk-free. Medical and cultural contexts matter: the Thai approach to health blends traditional understandings with modern science, and public health campaigns must reflect this integration. The Ministry of Public Health has signaled the need for updated guidelines, clearer product labeling, and more comprehensive screening for cannabis use during cardiovascular risk assessments.
Thai clinicians stress a cautious stance for patients with heart disease, hypertension, or a family history of cardiovascular problems. Leading Thai hospitals advocate conversations between doctors and patients about cannabis use, especially when considering medicinal products. Officials also highlight the importance of avoiding tobacco and maintaining overall heart-healthy lifestyles in the context of cannabis exposure.
Looking ahead, experts expect cardiovascular events linked to cannabis to rise if awareness and regulation lag. Western countries that legalized cannabis have seen increases in emergency room visits for palpitations, chest pain, and strokes; Thai authorities worry about similar patterns if prevention and education do not keep pace.
To protect communities, several recommendations emerge: improve labeling and consumer information on cannabis products; fund research into product safety and adulterants; and implement culturally tailored education that communicates cardiovascular risks to families, teachers, and youths, not just patients.
For individuals, the takeaway is clear. People with heart disease, high blood pressure, or a family history of cardiovascular problems should consult healthcare professionals before using cannabis in any form. Those considering medicinal cannabis should seek guidance from cardiovascular specialists. Parents and educators are encouraged to have open discussions about cannabis’s risks alongside its potential benefits.
As Thailand continues to shape its cannabis landscape, researchers urge policy makers, clinicians, and the public to prioritize evidence-based decisions. Understanding the cardiovascular implications of cannabis will help protect Thai communities while balancing medical access, economic considerations, and social responsibility.